---
document_datetime: 2025-12-02 04:50:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lysakare.html
document_name: lysakare.html
version: success
processing_time: 0.1284003
conversion_datetime: 2025-12-26 20:04:42.790684
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# LysaKare

[RSS](/en/individual-human-medicine.xml/67224)

##### Authorised

This medicine is authorised for use in the European Union

arginine / lysine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on LysaKare](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76170)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

LysaKare is a medicine used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium ( 177 Lu) oxodotreotide.

LysaKare is for use in adults and contains the active substances arginine and lysine.

Expand section

Collapse section

## How is LysaKare used?

LysaKare is given by infusion (drip) in to a vein over 4 hours. Infusion with LysaKare is started 30 minutes before the patient is given lutetium ( 177 Lu) oxodotreotide (also by infusion).

Because LysaKare can cause nausea (feeling sick) and vomiting, patients will be given medicines to prevent nausea and vomiting before receiving LysaKare.

LysaKare can only be obtained with a prescription and should only be given by a healthcare professional experienced in the use of radioactive medicines. For more information about using LysaKare, see the package leaflet or contact your doctor or pharmacist.

## How does LysaKare work?

Radiation from lutetium ( 177 Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. The active substances in LysaKare, arginine and lysine, interfere with the passage of lutetium ( 177 Lu) oxodotreotide through these kidney tubules. As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation.

## What benefits of LysaKare have been shown in studies?

Because the use of arginine and lysine to protect the kidneys during this type of cancer treatment is well established, the company presented data from the scientific literature. These included data from over 1,200 cancer patients treated with lutetium ( 177 Lu) oxodotreotide, which showed that arginine and lysine were effective at preventing kidney damage.

In another published study involving 229 patients, measurement of creatinine clearance (an indication of how well the kidneys are working) did not show kidney damage 14 months after patients were treated with arginine and lysine at the same time as lutetium ( 177 Lu) oxodotreotide.

## What are the risks associated with LysaKare?

The most common side effects with LysaKare (which may affect more than 1 in 10 people) are nausea and vomiting. LysaKare is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known. Side effects with LysaKare are usually mild or moderate.

LysaKare must not be given to patients with high levels of potassium in the blood if this has not been corrected before treatment.

For the full list of side effects and restrictions with LysaKare, see the package leaflet.

## Why is LysaKare authorised in the EU?

The use of arginine and lysine during treatment with lutetium ( 177 Lu) oxodotreotide has been shown to reduce kidney damage and allow patients to be given an effective dose of radioactive treatment for their cancer. The main risk with LysaKare is a dangerous rise of blood potassium levels but this side effect can be managed if recognised and treated appropriately. Information on how to do this has been included in the product information. The European Medicines Agency therefore decided that LysaKare's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of LysaKare?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of LysaKare have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of LysaKare are continuously monitored. Side effects reported with LysaKare are carefully evaluated and any necessary action taken to protect patients.

## Other information about LysaKare

LysaKare received a marketing authorisation valid throughout the EU on 25 July 2019.

LysaKare : EPAR - Medicine overview

Reference Number: EMA/378037/2019

English (EN) (105.76 KB - PDF)

**First published:** 30/07/2019

[View](/en/documents/overview/lysakare-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-581)

български (BG) (119.17 KB - PDF)

**First published:**

30/07/2019

[View](/bg/documents/overview/lysakare-epar-medicine-overview_bg.pdf)

español (ES) (98 KB - PDF)

**First published:**

30/07/2019

[View](/es/documents/overview/lysakare-epar-medicine-overview_es.pdf)

čeština (CS) (118.1 KB - PDF)

**First published:**

30/07/2019

[View](/cs/documents/overview/lysakare-epar-medicine-overview_cs.pdf)

dansk (DA) (98.01 KB - PDF)

**First published:**

30/07/2019

[View](/da/documents/overview/lysakare-epar-medicine-overview_da.pdf)

Deutsch (DE) (101.42 KB - PDF)

**First published:**

30/07/2019

[View](/de/documents/overview/lysakare-epar-medicine-overview_de.pdf)

eesti keel (ET) (88.43 KB - PDF)

**First published:**

30/07/2019

[View](/et/documents/overview/lysakare-epar-medicine-overview_et.pdf)

ελληνικά (EL) (117.6 KB - PDF)

**First published:**

30/07/2019

[View](/el/documents/overview/lysakare-epar-medicine-overview_el.pdf)

français (FR) (99.85 KB - PDF)

**First published:**

30/07/2019

[View](/fr/documents/overview/lysakare-epar-medicine-overview_fr.pdf)

hrvatski (HR) (115.64 KB - PDF)

**First published:**

30/07/2019

[View](/hr/documents/overview/lysakare-epar-medicine-overview_hr.pdf)

italiano (IT) (97.63 KB - PDF)

**First published:**

30/07/2019

[View](/it/documents/overview/lysakare-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (128.61 KB - PDF)

**First published:**

30/07/2019

[View](/lv/documents/overview/lysakare-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (116.6 KB - PDF)

**First published:**

30/07/2019

[View](/lt/documents/overview/lysakare-epar-medicine-overview_lt.pdf)

magyar (HU) (115.11 KB - PDF)

**First published:**

30/07/2019

[View](/hu/documents/overview/lysakare-epar-medicine-overview_hu.pdf)

Malti (MT) (116.87 KB - PDF)

**First published:**

30/07/2019

[View](/mt/documents/overview/lysakare-epar-medicine-overview_mt.pdf)

Nederlands (NL) (98.92 KB - PDF)

**First published:**

30/07/2019

[View](/nl/documents/overview/lysakare-epar-medicine-overview_nl.pdf)

polski (PL) (119.82 KB - PDF)

**First published:**

30/07/2019

[View](/pl/documents/overview/lysakare-epar-medicine-overview_pl.pdf)

português (PT) (99.2 KB - PDF)

**First published:**

30/07/2019

[View](/pt/documents/overview/lysakare-epar-medicine-overview_pt.pdf)

română (RO) (115.13 KB - PDF)

**First published:**

30/07/2019

[View](/ro/documents/overview/lysakare-epar-medicine-overview_ro.pdf)

slovenčina (SK) (116.93 KB - PDF)

**First published:**

30/07/2019

[View](/sk/documents/overview/lysakare-epar-medicine-overview_sk.pdf)

slovenščina (SL) (114.87 KB - PDF)

**First published:**

30/07/2019

[View](/sl/documents/overview/lysakare-epar-medicine-overview_sl.pdf)

Suomi (FI) (95.82 KB - PDF)

**First published:**

30/07/2019

[View](/fi/documents/overview/lysakare-epar-medicine-overview_fi.pdf)

svenska (SV) (97.64 KB - PDF)

**First published:**

30/07/2019

[View](/sv/documents/overview/lysakare-epar-medicine-overview_sv.pdf)

LysaKare : EPAR - Risk management plan

English (EN) (1.69 MB - PDF)

**First published:** 30/07/2019

**Last updated:** 28/04/2025

[View](/en/documents/rmp/lysakare-epar-risk-management-plan_en.pdf)

## Product information

LysaKare : EPAR - Product information

English (EN) (422.12 KB - PDF)

**First published:** 30/07/2019

**Last updated:** 07/08/2025

[View](/en/documents/product-information/lysakare-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-280)

български (BG) (534.67 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/bg/documents/product-information/lysakare-epar-product-information_bg.pdf)

español (ES) (412.36 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/es/documents/product-information/lysakare-epar-product-information_es.pdf)

čeština (CS) (521.8 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/cs/documents/product-information/lysakare-epar-product-information_cs.pdf)

dansk (DA) (428.66 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/da/documents/product-information/lysakare-epar-product-information_da.pdf)

Deutsch (DE) (320.22 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/de/documents/product-information/lysakare-epar-product-information_de.pdf)

eesti keel (ET) (418.9 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/et/documents/product-information/lysakare-epar-product-information_et.pdf)

ελληνικά (EL) (531.09 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/el/documents/product-information/lysakare-epar-product-information_el.pdf)

français (FR) (438.58 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/fr/documents/product-information/lysakare-epar-product-information_fr.pdf)

hrvatski (HR) (530.92 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/hr/documents/product-information/lysakare-epar-product-information_hr.pdf)

íslenska (IS) (473.5 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/is/documents/product-information/lysakare-epar-product-information_is.pdf)

italiano (IT) (413.44 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/it/documents/product-information/lysakare-epar-product-information_it.pdf)

latviešu valoda (LV) (501.08 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/lv/documents/product-information/lysakare-epar-product-information_lv.pdf)

lietuvių kalba (LT) (478.26 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/lt/documents/product-information/lysakare-epar-product-information_lt.pdf)

magyar (HU) (470.52 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/hu/documents/product-information/lysakare-epar-product-information_hu.pdf)

Malti (MT) (528.27 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/mt/documents/product-information/lysakare-epar-product-information_mt.pdf)

Nederlands (NL) (427.99 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/nl/documents/product-information/lysakare-epar-product-information_nl.pdf)

norsk (NO) (431.05 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/no/documents/product-information/lysakare-epar-product-information_no.pdf)

polski (PL) (495.78 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/pl/documents/product-information/lysakare-epar-product-information_pl.pdf)

português (PT) (418.98 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/pt/documents/product-information/lysakare-epar-product-information_pt.pdf)

română (RO) (496.58 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/ro/documents/product-information/lysakare-epar-product-information_ro.pdf)

slovenčina (SK) (514.02 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/sk/documents/product-information/lysakare-epar-product-information_sk.pdf)

slovenščina (SL) (511.78 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/sl/documents/product-information/lysakare-epar-product-information_sl.pdf)

Suomi (FI) (444.67 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/fi/documents/product-information/lysakare-epar-product-information_fi.pdf)

svenska (SV) (401.4 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/sv/documents/product-information/lysakare-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000269283 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

LysaKare : EPAR - All authorised presentations

English (EN) (50.11 KB - PDF)

**First published:** 30/07/2019

**Last updated:** 07/08/2025

[View](/en/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-447)

български (BG) (57.08 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/bg/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_bg.pdf)

español (ES) (52.63 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/es/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.55 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/cs/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (53.04 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/da/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (68.82 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/de/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.76 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/et/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (55.13 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/el/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_el.pdf)

français (FR) (51.56 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/fr/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.95 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/hr/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (53.74 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/is/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_is.pdf)

italiano (IT) (51.64 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/it/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.59 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/lv/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (54.7 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/lt/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.28 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/hu/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.62 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/mt/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/nl/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (54.17 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/no/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_no.pdf)

polski (PL) (74.15 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/pl/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_pl.pdf)

português (PT) (52.81 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/pt/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.45 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/ro/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.08 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/sk/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.1 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/sl/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (48.34 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/fi/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.37 KB - PDF)

**First published:**

30/07/2019

**Last updated:**

07/08/2025

[View](/sv/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine LysaKare Active substance

- L-arginine hydrochloride
- L-lysine hydrochloride

International non-proprietary name (INN) or common name

- arginine
- lysine

Therapeutic area (MeSH) Radiation Injuries Anatomical therapeutic chemical (ATC) code V03AF11

### Pharmacotherapeutic group

Detoxifying agents for antineoplastic treatment

### Therapeutic indication

LysaKare is indicated for reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.

## Authorisation details

EMA product number EMEA/H/C/004541 Marketing authorisation holder

Advanced Accelerator Applications

Advanced Accelerator Applications

Opinion adopted 29/05/2019 Marketing authorisation issued 25/07/2019 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

LysaKare : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.9 KB - PDF)

**First published:** 21/05/2025

**Last updated:** 07/08/2025

[View](/en/documents/procedural-steps-after/lysakare-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

LysaKare : EPAR -  Procedural steps taken and scientific information after authorisation (archive)

English (EN) (165.8 KB - PDF)

**First published:** 10/11/2021

**Last updated:** 21/05/2025

[View](/en/documents/procedural-steps-after/lysakare-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

LysaKare : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/363968/2019

English (EN) (1.6 MB - PDF)

**First published:** 30/07/2019

[View](/en/documents/assessment-report/lysakare-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for LysaKare

Adopted

Reference Number: EMA/CHMP/276812/2019

English (EN) (114.41 KB - PDF)

**First published:** 29/05/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lysakare_en.pdf)

#### News on LysaKare

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-29 May 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-29-may-2019) 29/05/2019

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

LysaKare : EPAR - Product information - tracked changes

English (EN) (128.29 KB - DOCX)

**First published:** 28/04/2025

**Last updated:** 07/08/2025

[View](/en/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-382)

български (BG) (134.76 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/bg/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_bg.docx)

español (ES) (129.22 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/es/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_es.docx)

čeština (CS) (121.21 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/cs/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (130.49 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/da/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (130.68 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/de/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (128.01 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/et/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (120.59 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/el/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_el.docx)

français (FR) (128.02 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/fr/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (133.78 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/hr/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (124.03 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/is/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_is.docx)

italiano (IT) (129.65 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/it/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (127.85 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/lv/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (130.29 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/lt/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (131.91 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/hu/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (128.98 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/mt/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (127.23 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/nl/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (130.44 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/no/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_no.docx)

polski (PL) (128.86 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/pl/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_pl.docx)

português (PT) (127.83 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/pt/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_pt.docx)

română (RO) (128.6 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/ro/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (132.1 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/sk/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (134.68 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/sl/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (127.38 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/fi/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (126.81 KB - DOCX)

**First published:**

28/04/2025

**Last updated:**

07/08/2025

[View](/sv/documents/product-information-tracked-changes/lysakare-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/08/2025

## Share this page

[Back to top](#main-content)